Immatics N.V. (IMTX)
Immatics N.V. is a clinical-stage biopharmaceutical firm dedicated to discovering and advancing T-cell receptor (TCR) based immunotherapies aimed at combating cancer, primarily within the United States. Its therapeutic strategy centers on targeted immunotherapies for solid tumors, utilizing two distinct approaches: adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. The company's ACTengine™ portfolio features several candidates in Phase I clinical trials. These include IMA201, designed to recognize melanoma-associated antigens 4 or 8 in solid tumor patients; IMA202, which targets melanoma-associated antigen 1 across various solid tumor types, such as squamous non-small cell lung carcinoma and hepatocellular carcinoma; and IMA203, aimed at preferentially expressed antigen in melanoma in adult patients with recurrent or treatment-resistant solid tumors. Additionally, IMA204, currently in preclinical stages, focuses on targeting tumor stroma cells. In its preclinical TCR Bispecifics pipeline, Immatics is advancing IMA401, which targets cancer testis antigens for solid tumor indications, and IMA402, also under investigation for solid tumor therapies. Other programs include IMA101 for cancer treatment and IMA301, an allogeneic cellular therapy candidate. Immatics has established strategic partnerships to bolster its development efforts. These include collaborations with GlaxoSmithKline Intellectual Property Development Limited for novel adoptive cell therapies across various cancer indications; MD Anderson Cancer Center for multiple T-cell and TCR-based adoptive cellular therapies; Celgene Switzerland LLC for additional novel adoptive cell therapies; and Genmab A/S to develop T-cell engaging bispecific immunotherapies for diverse cancer indications. The company's headquarters are situated in Tübingen, Germany.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
Immatics N.V.
No splits on record
Nothing in IMTX's public trading history: no forward or reverse split has affected the share count.
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Revenue | $53.92M | $174.1M | $60.33M | $193.09M | $38.84M | $34.92M | $20.61M | $4.21M |
| YoY Growth | -69.0% | 188.6% | -68.8% | 397.2% | 11.2% | 69.4% | 389.4% | - |
| Cost of Revenue | $0 | $0 | $0 | $0 | $0 | $74.95M | $44.79M | $37.95M |
| Gross Profit | $53.92M | $174.1M | $60.33M | $193.09M | $38.84M | -$40.03M | -$24.18M | -$33.74M |
| Gross Margin | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | -114.7% | -117.3% | -801.1% |
| Research and Development | $205.38M | $165.43M | $132.57M | $119.29M | $97.84M | $74.95M | $44.79M | $37.95M |
| Selling, General, and Administrative | $57.18M | $51.89M | $42.67M | $40.36M | $37.77M | $38.19M | $13.13M | $8.56M |
| Other | -$5.29M | -$87K | -$1.27M | -$29K | -$363K | -$75.29M | -$430K | -$3.86M |
| Total Operating Expenses | $257.27M | $217.24M | $173.97M | $159.62M | $135.24M | $37.85M | $57.49M | $42.65M |
| Operating Income (EBIT) | -$203.35M | -$43.14M | -$113.65M | $33.46M | -$96.41M | -$77.89M | -$36.88M | -$38.44M |
| Operating Margin | -377.1% | -24.8% | -188.4% | 17.3% | -248.2% | -223.1% | -178.9% | -912.7% |
| Interest Expense | $1.06M | $990K | $928K | $1.16M | $632K | $0 | $190K | $18K |
| Interest Income | $19.19M | $27.93M | $15.47M | $2.77M | $149K | $627K | $883K | $566K |
| Other Income (Expense) | -$18.34M | $66.99M | $5.29M | $13.5M | -$7.87M | -$158.78M | $588K | $2.29M |
| Income Before Tax (EBT) | -$221.69M | $23.85M | -$108.36M | $46.96M | -$104.27M | -$236.67M | -$36.29M | -$36.15M |
| Income Tax Expense | -$2.22M | $6.85M | -$2.62M | $16.01M | $0 | $0 | $0 | $0 |
| Net Income | -$219.47M | $17M | -$105.74M | $30.95M | -$104.27M | -$236.05M | -$35.46M | -$35.13M |
| Net Income Margin | -407.0% | 9.8% | -175.3% | 16.0% | -268.5% | -676.0% | -172.0% | -834.1% |
| Supplementary Data | ||||||||
| EPS | -1.54 | 0.14 | -1.18 | 0.56 | -1.48 | -4.40 | -0.50 | -0.50 |
| Diluted EPS | -1.54 | 0.14 | -1.18 | 0.55 | -1.48 | -4.40 | -0.50 | -0.50 |
| Weighted Average OS | 122.35M | 106.80M | 80.55M | 66.99M | 62.91M | 48.00M | 62.91M | 62.91M |
| EBITDA | -$206.78M | $38.5M | -$99.35M | $55.91M | -$97.77M | -$72.94M | -$31.79M | -$33.7M |
| EBITDA Margin | -383.5% | 22.1% | -164.7% | 29.0% | -251.7% | -208.9% | -154.3% | -800.1% |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Assets | ||||||||
| Current Assets | ||||||||
| Cash and Cash Equivalents | $386.3M | $264.49M | $244.08M | $165.93M | $148.58M | $231.85M | $115.47M | $43.98M |
| Short-Term Investments | $137.83M | $410.8M | $231.73M | $238.73M | $13.54M | $27.31M | $17.9M | $14.64M |
| Cash and Short-Term Investments | $524.12M | $675.29M | $475.81M | $404.66M | $162.12M | $259.17M | $133.37M | $58.62M |
| Accounts Receivable | $7.68M | $7.54M | $6.41M | $1.24M | $2.64M | $3.27M | $3.04M | $2.03M |
| Inventory | $0 | $0 | $0 | $0 | $0 | $0 | $1.38M | $0 |
| Other Current Assets | $16.61M | $7.05M | $7.95M | $3.79M | $1.06M | $1.9M | $743K | $1.12M |
| Total Current Assets | $562.84M | $703.34M | $502.04M | $421.36M | $170.05M | $267M | $138.53M | $61.77M |
| Long-Term Assets | ||||||||
| Property, Plant & Equipment Net | $61.3M | $71.18M | $63.74M | $29.59M | $22.89M | $15.66M | $8.95M | $4.48M |
| Goodwill | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Intangible Assets | $1.77M | $1.82M | $1.7M | $1.82M | $1.47M | $1.02M | $1.13M | $1.16M |
| Long-Term Investments | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Deferred Tax Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Long-Term Assets | $2.07M | $1.4M | $2.25M | $2.84M | $711K | $811K | $1.41M | $1.1M |
| Total Long-Term Assets | $65.14M | $74.4M | $67.7M | $34.26M | $25.07M | $17.49M | $11.48M | $6.74M |
| Other Assets | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Assets | $627.98M | $777.73M | $569.73M | $455.62M | $195.11M | $284.49M | $150.01M | $68.5M |
| Liabilities | ||||||||
| Current Liabilities | ||||||||
| Accounts Payable | $380K | $11.3M | $8.56M | $14.59M | $3.36M | $2.85M | $5.44M | $5.37M |
| Short-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Current Income Tax Payable | $0 | $4.21M | $8.78M | $8.63M | $1.97M | $1.32M | $812K | $0 |
| Current Unearned Revenue | $17.66M | $40.12M | $112.17M | $72.57M | $56.31M | $52.06M | $66.62M | $24.3M |
| Other Current Liabilities | $6.22M | $5.32M | $22.88M | $18.51M | $31.33M | $19.08M | $73K | $992K |
| Total Current Liabilities | $48.03M | $75.96M | $174.9M | $118.93M | $106.3M | $86.56M | $77.42M | $29.98M |
| Long-Term Liabilities | ||||||||
| Long-Term Debt | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Long-Term Unearned Revenue | $20.71M | $38.16M | $129.07M | $84.64M | $53.88M | $95.49M | $113.85M | $48.52M |
| Long-Term Deferred Tax Liabilities | $4.25M | $6.48M | $8.34M | $10.96M | $0 | $0 | $0 | $0 |
| Other Long-Term Liabilities | $0 | $0 | $4K | $47K | $76K | $0 | $2.33M | $246K |
| Total Long-Term Liabilities | $39.34M | $59.57M | $151.71M | $109.5M | $61.93M | $100.3M | $118.22M | $48.77M |
| Other Liabilities | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Total Liabilities | $87.37M | $135.52M | $326.61M | $228.43M | $168.23M | $186.86M | $195.64M | $78.75M |
| Stockholders' Equity | ||||||||
| Preferred Stock | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Common Stock | $1.5M | $1.36M | $946K | $857K | $703K | $703K | $1.3M | $1.3M |
| Retained Earnings | -$877.73M | -$658.64M | -$675.64M | -$569.89M | -$600.84M | -$496.57M | -$260.52M | -$225.25M |
| Comprehensive Income & Other | -$9.59M | $1.15M | -$1.83M | -$1.65M | -$4.41M | -$8.33M | -$860K | -$828K |
| Other Stockholders' Equity | $1.42B | $1.3B | $917.81M | $796.22M | $627.03M | $593.5M | $212.46M | $212.33M |
| Total Equity | $540.61M | $642.21M | $243.12M | $227.19M | $26.88M | $97.63M | -$46.76M | -$11.63M |
| Minority Interest | $0 | $0 | $0 | $0 | $0 | $0 | $1.14M | $1.38M |
| Total Liabilities and Equity | $627.98M | $777.73M | $569.73M | $455.62M | $195.11M | $284.49M | $148.87M | $67.12M |
| Supplementary Data | ||||||||
| Total Debt | $17.46M | $18.1M | $17.21M | $16.27M | $11.01M | $6.91M | $3.61M | $0 |
| Net Debt | -$368.84M | -$246.39M | -$226.87M | -$149.66M | -$137.57M | -$224.94M | -$111.85M | -$43.98M |
| Period | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 |
|---|---|---|---|---|---|---|---|---|
| Currency | USD | USD | USD | USD | USD | USD | USD | USD |
| Period Ending | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
| Operating Activities | ||||||||
| Net Income | -$210.81M | $17M | -$105.74M | $41.91M | -$104.27M | -$256.53M | -$36.29M | -$36.15M |
| Depreciation & Amortization | $13.85M | $13.66M | $8.08M | $7.78M | $5.88M | $4.94M | $4.31M | $2.43M |
| Deferred Income Tax | $0 | $6.85M | $0 | $5.05M | $12.46M | -$4.42M | $696K | $549K |
| Stock-Based Compensation | $0 | $19.71M | $23.13M | $25.22M | $29.5M | $25.64M | $952K | $1.65M |
| Changes in Working Capital: | ||||||||
| Accounts Receivable | -$260K | -$1.97M | -$3.33M | -$479K | $636K | -$328K | -$629K | -$196K |
| Inventory | $0 | $0 | -$94.11M | $0 | $0 | $0 | $0 | $0 |
| Accounts Payable | -$40.36M | $0 | $94.11M | $50.9M | -$35.51M | -$26.13M | $110.53M | $48.86M |
| Other Working Capital | -$6.55M | -$181.11M | $94.53M | -$8.79M | -$540K | -$1.79M | -$1.67M | $6.27M |
| Total Working Capital Change | -$47.18M | -$183.08M | $91.2M | $41.62M | -$35.41M | -$28.24M | $108.23M | $54.93M |
| Other Non-Cash Items | $54.6M | -$50.68M | $3.7M | -$9.72M | $484K | $162.96M | $1.39M | -$303K |
| Net Cash from Operating | -$189.54M | -$176.55M | $20.36M | $111.87M | -$91.37M | -$95.64M | $79.28M | $23.11M |
| Investing Activities | ||||||||
| Capital Expenditures | -$7.3M | -$18.18M | -$34.41M | -$6.94M | -$6.32M | -$8.41M | -$2.5M | -$566K |
| Acquisitions | $0 | $0 | $0 | -$223.34M | $616K | $116K | $102K | $108K |
| Purchases of Investments | -$363M | -$503.13M | -$464M | -$241.68M | -$12.62M | -$92.65M | -$86.93M | -$14.64M |
| Sales of Investments | $590.06M | $351.29M | $463.35M | $14.18M | $27.31M | $83.24M | $83.66M | $0 |
| Other Investing Activities | $0 | -$230K | -$9K | $223.4M | -$616K | -$116K | $7K | $105K |
| Net Cash from Investing | $219.76M | -$170.25M | -$35.07M | -$234.38M | $8.37M | -$17.82M | -$5.65M | -$15.1M |
| Financing Activities | ||||||||
| Debt Repaid | - | $2.25M | $4.3M | $3.18M | $3.02M | $2.34M | $2.08M | - |
| Common Stock Issuance | $107.65M | $383.21M | $101M | $150.25M | $105K | $243.46M | $0 | $26.42M |
| Common Stock Repurchases | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Dividends Paid | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 |
| Other Financing Activities | -$3.18M | -$23.81M | -$2.28M | -$8.86M | $0 | -$8.87M | $0 | $0 |
| Net Cash from Financing | $104.47M | $357.15M | $94.42M | $138.21M | -$2.92M | $232.25M | -$2.08M | $26.42M |
| Forex Effect | $18.5M | $10.06M | -$1.57M | $1.65M | $2.65M | -$2.4M | -$67K | $150K |
| Net Change in Cash | $153.19M | $20.42M | $78.15M | $17.34M | -$83.27M | $116.39M | $71.49M | $34.58M |
| Supplementary Data | ||||||||
| Operating Cash Flow | -$189.54M | -$176.55M | $20.36M | $111.87M | -$91.37M | -$95.64M | $79.28M | $23.11M |
| Capital Expenditure | -$7.04M | -$18.41M | -$34.59M | -$6.94M | -$6.32M | -$8.41M | -$2.5M | -$566K |
| Free Cash Flow | -$196.58M | -$194.96M | -$14.22M | $104.92M | -$97.69M | -$104.05M | $76.79M | $22.54M |
| Cash at Beginning | $233.1M | $244.08M | $165.93M | $148.58M | $231.85M | $115.47M | $43.98M | $9.4M |
| Cash at End | $386.3M | $264.49M | $244.08M | $165.93M | $148.58M | $231.85M | $115.47M | $43.98M |